Evidence map›Paper›PMID 33064630›Full record

ReviewHuman vaccines & immunotherapeutics2021

Evidence and speculations: vaccines and therapeutic options for COVID-19 pandemic.

Rabeea Siddique, Qian Bai, Muhammad Adnan Shereen, Ghulam Nabi, Guang Han, Farooq Rashid, Saeed Ahmed, Aigerim Benzhanova, Mengzhou Xue, Suliman Khan

Abstract readReview
In one paragraph

Review in Human vaccines & immunotherapeutics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Rabeea SiddiqueDepartment of Cerebrovascular Diseases, The Second Affiliated Hospital of Zhengzhou University, Zhengzhou, PR China.
Qian BaiDepartment of Cerebrovascular Diseases, The Second Affiliated Hospital of Zhengzhou University, Zhengzhou, PR China.
Muhammad Adnan ShereenState Key Laboratory of Virology, College of Life Sciences, Wuhan University, Wuhan, PR China.ORCID 0000-0002-0914-0697
Ghulam NabiState Key Laboratory of Virology, Key Laboratory of Animal Physiology, Biochemistry and Molecular Biology of Hebei Province, College of Life Sciences, Hebei Normal University, Shijiazhuang, China.
Guang HanDepartment of Radiation Oncology, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Farooq RashidSchool of Public Health, Department of Epidemiology, Southern Medical University, Guangzhou, China.
Saeed AhmedDepartment of Cerebrovascular Diseases, The Second Affiliated Hospital of Zhengzhou University, Zhengzhou, PR China.
Aigerim BenzhanovaDepartment of Cerebrovascular Diseases, The Second Affiliated Hospital of Zhengzhou University, Zhengzhou, PR China.
Mengzhou XueDepartment of Cerebrovascular Diseases, The Second Affiliated Hospital of Zhengzhou University, Zhengzhou, PR China.
Suliman KhanDepartment of Cerebrovascular Diseases, The Second Affiliated Hospital of Zhengzhou University, Zhengzhou, PR China.ORCID 0000-0003-4954-0748

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A novel coronavirus (2019-nCov) emerged in China, at the end of December 2019 which posed an International Public Health Emergency, and later declared as a global pandemic by the World Health Organization (WHO). The International Committee on Taxonomy of Viruses (ICTV) named it SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus-2), while the disease was named COVID-19 (Coronavirus Disease- 2019). Many questions related to the exact mode of transmission, animal origins, and antiviral therapeutics are not clear yet. Nevertheless, it is required to urgently launch a new protocol to evaluate the side effects of unapproved vaccines and antiviral therapeutics to accelerate the clinical application of new drugs. In this review, we highlight the most salient characteristics and recent findings of COVID-19 disease, molecular virology, interspecies mechanisms, and health consequences related to this disease.

Indexed as

Adenosine MonophosphateAlanineAnimalsAntiviral AgentsChiropteraCoronavirus Protease InhibitorsCOVID-19COVID-19 Drug TreatmentCOVID-19 VaccinesHumansLopinavirRitonavirSARS-CoV-2Virus AttachmentVirus InternalizationAdenosine MonophosphateAlanineAntiviral AgentsCoronavirus Protease InhibitorsCOVID-19 VaccinesLopinavirremdesivirRitonavircovid-19genomehuman healthSARS-CoV-2therapeutic optionsvaccine development

Identifiers

PMID33064630
PMCPMC8018497

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.